NCCN task force report: Management of patients with gastrointestinal stromal tumor (GIST) - Update of the NCCN clinical practice guidelines Journal Article


Authors: Demetri, G. D.; Benjamin, R. S.; Blanke, C. D.; Blay, J. Y.; Casali, P.; Choi, H.; Corless, C. L.; Debiec-Rychter, M.; DeMatteo, R. P.; Ettinger, D. S.; Fisher, G. A.; Fletcher, C. D. M.; Gronchi, A.; Hohenberger, P.; Hughes, M.; Joensuu, H.; Judson, I.; Le Cesne, A.; Maki, R. G.; Morse, M.; Pappo, A. S.; Pisters, P. W. T.; Raut, C. P.; Reichardt, P.; Tyler, D. S.; Van Den Abbeele, A. D.; von Mehren, M.; Wayne, J. D.; Zalcberg, J.
Article Title: NCCN task force report: Management of patients with gastrointestinal stromal tumor (GIST) - Update of the NCCN clinical practice guidelines
Abstract: The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib) for GIST. Because of these changes, NCCN organized a multidisciplinary panel composed of experts in the fields of medical oncology, molecular diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and Australia. The Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize our understanding and treatment of GIST. © Journal of the National Comprehensive Cancer Network 2007.
Keywords: cancer chemotherapy; cancer survival; cancer surgery; clinical trial; fatigue; histopathology; neutropenia; review; placebo; sunitinib; diarrhea; drug dose reduction; drug withdrawal; hypertension; side effect; united states; anorexia; gastrointestinal stromal tumor; imatinib; diagnostic procedure; anemia; bone marrow suppression; bleeding; mucosa inflammation; nausea; vomiting; nccn clinical practice guidelines; dexamethasone; practice guideline; oncology; abdominal pain; drug dose escalation; rash; sarcoma; europe; patient care; liver metastasis; phenobarbital; paracetamol; warfarin; stomach cancer; australia; skin discoloration; loperamide; clarithromycin; kit; ketoconazole; intestine obstruction; hypothyroidism; levothyroxine; gastrointestinal tract; gist; cyclosporin a; dyspepsia; hand foot syndrome; alprazolam; tyrosine kinase; rifampicin; simvastatin; cyclosporin; phenytoin; atropine; fluid retention; aprepitant; carbamazepine; erythromycin; itraconazole; pimozide; rifabutin; rifapentine; muscle cramp; diphenhydramine; cd117; levothyroxine sodium; abscess; loose feces; amlodipine; antacid agent; abdominal tumor; gastric mass; small bowel tumor; nifedipine; nitrendipine
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 5
Issue: Suppl. 2
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2007-01-01
Start Page: S1
End Page: S29; quiz S30
Language: English
PROVIDER: scopus
PUBMED: 17624289
DOI/URL:
Notes: - "Export Date: 17 November 2011" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Ronald P DeMatteo
    637 DeMatteo
  2. Robert Maki
    238 Maki
Related MSK Work